Improving the duration of immunity for FMD vaccines

提高口蹄疫疫苗的免疫力持续时间

基本信息

  • 批准号:
    BB/N012682/1
  • 负责人:
  • 金额:
    $ 25.5万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2016
  • 资助国家:
    英国
  • 起止时间:
    2016 至 无数据
  • 项目状态:
    已结题

项目摘要

Foot-and-mouth disease (FMD) is a highly contagious viral disease of cattle, pigs, sheep and goats. Currently chemically inactivated, oil adjuvanted FMD vaccines are a critical element in FMD control. Although these vaccines are effective in pigs and ruminants, protective immunity is short-lived (3 months).The need for repeated vaccination significantly constrains vaccine-based control programmes. More appropriate vaccine strains that induce broader protection, together with identification of novel adjuvants that help to stimulate a greater duration of immunity would make a significant contribution to FMD control. In a BBSRC/DFID funded grant we have identified a vaccine strain that provided broader protection and a novel adjuvant that enhanced immunity. The newly formulated vaccine protected all vaccinated animals upon live virus challenge. Therefore we are interested to investigate further whether this new vaccine formulation could achieve longer duration immunity.
口蹄疫是牛、猪、绵羊和山羊的一种高度传染性病毒性疾病。目前化学灭活的油佐剂口蹄疫疫苗是控制口蹄疫的关键因素。虽然这些疫苗对猪和反刍动物有效,但保护性免疫是短暂的(3个月)。重复接种疫苗的需要严重限制了基于疫苗的控制规划。能够产生更广泛保护作用的更合适的疫苗菌株,以及有助于刺激更长的免疫持续时间的新型佐剂的鉴定,将对口蹄疫控制作出重大贡献。在BBSRC/DFID资助的资助下,我们已经确定了一种疫苗株,它提供了更广泛的保护和一种增强免疫力的新型佐剂。新配制的疫苗保护所有接种过疫苗的动物免受活病毒攻击。因此,我们有兴趣进一步研究这种新疫苗制剂是否能实现更长时间的免疫。

项目成果

期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Emergence of antigenic variants within serotype A FMDV in the Middle East with antigenically critical amino acid substitutions.
  • DOI:
    10.1016/j.vaccine.2016.02.057
  • 发表时间:
    2016-06-08
  • 期刊:
  • 影响因子:
    5.5
  • 作者:
    Mahapatra M;Statham B;Li Y;Hammond J;Paton D;Parida S
  • 通讯作者:
    Parida S
Genetic and antigenic characterization of serotype O FMD viruses from East Africa for the selection of suitable vaccine strain.
  • DOI:
    10.1016/j.vaccine.2017.10.040
  • 发表时间:
    2017-12-14
  • 期刊:
  • 影响因子:
    5.5
  • 作者:
    Lloyd-Jones K;Mahapatra M;Upadhyaya S;Paton DJ;Babu A;Hutchings G;Parida S
  • 通讯作者:
    Parida S
Molecular Basis of Antigenic Drift in Serotype O Foot-and-Mouth Disease Viruses (2013-2018) from Southeast Asia.
  • DOI:
    10.3390/v13091886
  • 发表时间:
    2021-09-21
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Upadhyaya S;Mahapatra M;Mioulet V;Parida S
  • 通讯作者:
    Parida S
Selection of vaccine strains for serotype O foot-and-mouth disease viruses (2007-2012) circulating in Southeast Asia, East Asia and Far East.
  • DOI:
    10.1016/j.vaccine.2017.10.099
  • 发表时间:
    2017-12-18
  • 期刊:
  • 影响因子:
    5.5
  • 作者:
    Mahapatra M;Upadhyaya S;Aviso S;Babu A;Hutchings G;Parida S
  • 通讯作者:
    Parida S
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Satya Parida其他文献

Satya Parida的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Satya Parida', 18)}}的其他基金

Next generation peste-des-petits ruminats (PPR) vaccines that differentiate between infected and vaccinated animals (DIVA) - proof of concept in sheep
下一代小反刍兽疫 (PPR) 疫苗可区分受感染动物和已接种动物 (DIVA) - 在绵羊身上进行概念验证
  • 批准号:
    BB/T004096/1
  • 财政年份:
    2020
  • 资助金额:
    $ 25.5万
  • 项目类别:
    Research Grant
Understanding the immune mechanism of host disease resistance and development of marker vaccines and DIVA tests for Peste des Petits Ruminants (PPR)
了解宿主抗病的免疫机制以及针对小反刍兽疫 (PPR) 标记疫苗和 DIVA 检测的开发
  • 批准号:
    BB/L004801/1
  • 财政年份:
    2014
  • 资助金额:
    $ 25.5万
  • 项目类别:
    Research Grant
ANIHWA CALL1:Improved Understanding of Epidemiology of PPR (IUEPPR)
ANIHWA CALL1:提高对小反刍兽疫流行病学的了解 (IUEPPR)
  • 批准号:
    BB/L013657/1
  • 财政年份:
    2013
  • 资助金额:
    $ 25.5万
  • 项目类别:
    Research Grant
UK-India Partnership for the control of FMD and PPR
英国与印度建立口蹄疫和小反刍兽疫控制伙伴关系
  • 批准号:
    BB/J020478/1
  • 财政年份:
    2012
  • 资助金额:
    $ 25.5万
  • 项目类别:
    Research Grant
Improving the quality of FMD vaccines by understanding the correlation of vaccine-induced protection with humoral and cellular immune responses
通过了解疫苗诱导的保护与体液和细胞免疫反应的相关性来提高 FMD 疫苗的质量
  • 批准号:
    BB/H009175/1
  • 财政年份:
    2011
  • 资助金额:
    $ 25.5万
  • 项目类别:
    Research Grant
UK-China partnership to control Peste-des-petits-ruminants (PPR)
中英合作控制小反刍兽疫 (PPR)
  • 批准号:
    BB/I026138/1
  • 财政年份:
    2011
  • 资助金额:
    $ 25.5万
  • 项目类别:
    Research Grant

相似海外基金

Mechanism of immune response to muscle-directed AAV gene transfer
肌肉定向 AAV 基因转移的免疫反应机制
  • 批准号:
    10717750
  • 财政年份:
    2023
  • 资助金额:
    $ 25.5万
  • 项目类别:
A Phase 2, randomized, double-blind, 4-arm, multicenter study to demonstrate the efficacy and safety of topical dosage formulations of a prescription drug product for actinic keratosis
一项 2 期、随机、双盲、4 组、多中心研究,旨在证明处方药局部剂量制剂治疗光化性角化病的有效性和安全性
  • 批准号:
    10820810
  • 财政年份:
    2023
  • 资助金额:
    $ 25.5万
  • 项目类别:
Development of a Novel Calcium Channel Therapeutic for the Treatment of Asthma
开发治疗哮喘的新型钙通道疗法
  • 批准号:
    10603554
  • 财政年份:
    2023
  • 资助金额:
    $ 25.5万
  • 项目类别:
R-5280, A Novel Modified Superior Resistant Starch Therapy for Type 1 Diabetes
R-5280,一种针对 1 型糖尿病的新型改良优质抗性淀粉疗法
  • 批准号:
    10759268
  • 财政年份:
    2023
  • 资助金额:
    $ 25.5万
  • 项目类别:
Optimization of rifamycins to overcome intrinsic resistance of nontuberculous mycobacteria to improve treatment of NTM lung disease
优化利福霉素以克服非结核分枝杆菌的内在耐药性,改善 NTM 肺病的治疗
  • 批准号:
    10713137
  • 财政年份:
    2023
  • 资助金额:
    $ 25.5万
  • 项目类别:
Duration and Function of Lung Tissue Resident CD8+ Memory T cells
肺组织驻留 CD8 记忆 T 细胞的持续时间和功能
  • 批准号:
    10607707
  • 财政年份:
    2023
  • 资助金额:
    $ 25.5万
  • 项目类别:
A prospective evaluation of the gut microbiome as a mediator of lymphoma treatment outcome and systemic immunity
肠道微生物组作为淋巴瘤治疗结果和全身免疫调节因子的前瞻性评估
  • 批准号:
    10419202
  • 财政年份:
    2022
  • 资助金额:
    $ 25.5万
  • 项目类别:
Investigational new drug enabling studies for the development of a topical fixed dose combination drug product to treat actinic keratosis and prevent cutaneous squamous cell carcinoma.
研究性新药使研究能够开发局部固定剂量组合药物产品,以治疗光化性角化病和预防皮肤鳞状细胞癌。
  • 批准号:
    10482509
  • 财政年份:
    2022
  • 资助金额:
    $ 25.5万
  • 项目类别:
Impact of HIV, oral microbiome and mycobiome on oral HPV persistence
HIV、口腔微生物组和真菌组对口腔 HPV 持久性的影响
  • 批准号:
    10683323
  • 财政年份:
    2022
  • 资助金额:
    $ 25.5万
  • 项目类别:
Impact of HIV, oral microbiome and mycobiome on oral HPV persistence
HIV、口腔微生物组和真菌组对口腔 HPV 持久性的影响
  • 批准号:
    10534011
  • 财政年份:
    2022
  • 资助金额:
    $ 25.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了